LEAD MODEL 304
Report
- Report Number
- 1644487-2025-10561
- Event Type
- Malfunction
- Date Received
- August 29, 2025
- Date of Event
- July 31, 2025
- Report Date
- October 10, 2025
- Manufacturer
- LIVANOVA USA, INC.
- Product Code
- LYJ
- UDI-DI
- 05425025750139
- PMA / PMN Number
- P970003
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- IN, US
- Reporter Occupation
- PHYSICIAN
- Health Professional
- Yes
Narratives
H6 PROBLEM CODES, CORRECTED DATA: INITIAL REPORT WAS INADVERTENTLY SUBMITTED WITH THE INCORRECT E2402, A072201, C0203, AND D1401 CODING.
LIVANOVA USA, INC. SUBMITS THIS REPORT TO COMPLY WITH 21 C.F.R. PART 803, THE MEDICAL DEVICE REPORTING REGULATION, BASED ON INFORMATION THAT LIVANOVA HAS OBTAINED, BUT MAY NOT HAVE BEEN ABLE TO INVESTIGATE OR VERIFY PRIOR TO THE DATE THE REPORT WAS REQUIRED BY THE FDA. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION, OR A CONCLUSION BY FDA OR ANYONE ELSE, THAT THE DEVICE, LIVANOVA, OR LIVANOVA'S EMPLOYEES CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. IN PARTICULAR, THIS REPORT DOES NOT CONSTITUTE AN ADMISSION BY ANYONE THAT THE PRODUCT DESCRIBED IN THIS REPORT HAS ANY "DEFECTS¿ OR "MALFUNCTIONS¿. THESE WORDS ARE INCORPORATED INTO THE FDA 3500A MEDWATCH FORM BY THE FDA, AND LIVANOVA OBJECTS TO THEIR USE.
ADDITIONAL INFORMATION WAS RECEIVED THAT THE PATIENT UNDERWENT A FULL REPLACEMENT DUE TO HIGH IMPEDANCE. THE SUSPECT DEVICE HAS NOT BEEN RECEIVED BY MANUFACTURER TO DATE. NO OTHER RELEVANT INFORMATION HAS BEEN RECEIVED TO DATE.
IT WAS REPORTED THAT THE PATIENT "HAS A LEAD IMPEDANCE ISSUE" PER HER NEUROLOGIST. NEUROLOGIST TO REFER FOR POSSIBLE LEAD REVISION AND GENERATOR REPLACEMENT. NO SURGICAL INTERVENTION HAS BEEN REPORTED TO DATE. NO ADDITIONAL RELEVANT INFORMATION HAS BEEN RECEIVED TO DATE.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 2221490 | LEAD MODEL 304 | LEAD | LYJ | LIVANOVA USA, INC. | 304-20 | 3680 | 05425025750139 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 52 YR | Female |